Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia
The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/4739512 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548746897915904 |
|---|---|
| author | Claudia Stefanutti Fabio Mazza Michael Steiner Gerald F. Watts Joel De Nève Daniela Pasqualetti Juergen Paal |
| author_facet | Claudia Stefanutti Fabio Mazza Michael Steiner Gerald F. Watts Joel De Nève Daniela Pasqualetti Juergen Paal |
| author_sort | Claudia Stefanutti |
| collection | DOAJ |
| description | The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55±9.3 years (mean ± SD), were enrolled in the study. PTX3 soluble protein levels in plasma were unchanged by 2 sessions of LA; however, a downregulation of mRNA expression for PTX3 was observed, starting with the first session of LA (p<0.001). The observed reduction was progressively increased in the interval between the first and second LA sessions to achieve a maximum decrease by the end of the second session. A statistically significantly greater treatment-effect correlation was observed in patients undergoing weekly treatments, compared with those undergoing treatment every 15 days. A progressive reduction in plasma levels of C-reactive protein was also seen from the first session of LA, with a statistically significant linear correlation for treatment-effect in the change in plasma levels of this established inflammatory marker (R2=0.99; p<0.001). Our findings suggest that LA has anti-inflammatory and endothelium protective effects beyond its well-established efficacy in lowering apoB100-containing lipoproteins. |
| format | Article |
| id | doaj-art-0524befb9eb94fcc9c4043d176355ca0 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-0524befb9eb94fcc9c4043d176355ca02025-02-03T06:13:06ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/47395124739512Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemiaClaudia Stefanutti0Fabio Mazza1Michael Steiner2Gerald F. Watts3Joel De Nève4Daniela Pasqualetti5Juergen Paal6Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, “Sapienza” University of Rome, “Umberto I” Hospital, Viale del Policlinico, 00161 Rome, ItalyExtracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, “Sapienza” University of Rome, “Umberto I” Hospital, Viale del Policlinico, 00161 Rome, ItalyMedizinisches Labor Rostock, Rostock, GermanyCardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, AustraliaLabOmics S.A., Nivelles, BelgiumExtracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, “Sapienza” University of Rome, “Umberto I” Hospital, Viale del Policlinico, 00161 Rome, ItalyFresenius Medical Care Deutschland GmbH, Bad Homburg, GermanyThe effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55±9.3 years (mean ± SD), were enrolled in the study. PTX3 soluble protein levels in plasma were unchanged by 2 sessions of LA; however, a downregulation of mRNA expression for PTX3 was observed, starting with the first session of LA (p<0.001). The observed reduction was progressively increased in the interval between the first and second LA sessions to achieve a maximum decrease by the end of the second session. A statistically significantly greater treatment-effect correlation was observed in patients undergoing weekly treatments, compared with those undergoing treatment every 15 days. A progressive reduction in plasma levels of C-reactive protein was also seen from the first session of LA, with a statistically significant linear correlation for treatment-effect in the change in plasma levels of this established inflammatory marker (R2=0.99; p<0.001). Our findings suggest that LA has anti-inflammatory and endothelium protective effects beyond its well-established efficacy in lowering apoB100-containing lipoproteins.http://dx.doi.org/10.1155/2016/4739512 |
| spellingShingle | Claudia Stefanutti Fabio Mazza Michael Steiner Gerald F. Watts Joel De Nève Daniela Pasqualetti Juergen Paal Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia Mediators of Inflammation |
| title | Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia |
| title_full | Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia |
| title_fullStr | Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia |
| title_full_unstemmed | Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia |
| title_short | Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia |
| title_sort | relationship between sustained reductions in plasma lipid and lipoprotein concentrations with apheresis and plasma levels and mrna expression of ptx3 and plasma levels of hscrp in patients with hyperlp a lipoproteinemia |
| url | http://dx.doi.org/10.1155/2016/4739512 |
| work_keys_str_mv | AT claudiastefanutti relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia AT fabiomazza relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia AT michaelsteiner relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia AT geraldfwatts relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia AT joeldeneve relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia AT danielapasqualetti relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia AT juergenpaal relationshipbetweensustainedreductionsinplasmalipidandlipoproteinconcentrationswithapheresisandplasmalevelsandmrnaexpressionofptx3andplasmalevelsofhscrpinpatientswithhyperlpalipoproteinemia |